paget's%20bone%20disease
PAGET'S BONE DISEASE
Paget's bone disease, also known as osteitis deformans, is characterized by a significant increase in bone resorption and turnover in localized parts of the skeleton causing enlargement and thickening of the bone that is disordered and architecturally unstable.
The prevalence increases with age, with men and women affected equally.
Genetic factors and/or viral infection may play a role in the etiology.
May affect one bone (monostotic) or several bones (polyostotic).
By decreasing frequency, involved bones may include pelvic bone and sacrum, spine, skull and femur, tibia, humeri and clavicles.

Surgical Intervention

  • Eg joint replacement, osteotomy, fracture repair
  • Surgical patients should be pretreated w/ bisphosphonates to prevent serious bleeding during surgery due to hypervascularity, a symptom of active Paget’s bone disease
    • No clinical trials yet on the recommended timing of such treatment
  • Recommended for:
    • Pagetic fracture repair
    • Knee realignment to decrease mechanical pain, esp in cases where pharmacotherapy is ineffective
    • Hip/knee replacement esp in cases where antiresorptive therapy or osteoarthritis (OA) treatment is ineffective
    • Relief of compression due to pagetic vertebrae on the spinal cord or nerve roots
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
21 Dec 2017
Vitamin C supplementation appears to yield significant reductions in glucose concentrations in patients with diabetes, particularly older individuals and those with more prolonged supplementation, according to a study.
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
01 Jun 2015
New drug applications approved by US FDA as of 15 – 31 May 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Jairia Dela Cruz, 27 Dec 2017
Individuals with obesity and high abdominal fat mass appear to have a twofold increased risk of developing psoriasis, as shown in a study. Long-term weight gain of ≥10 kg is also associated with a substantially increased risk.